Deerfield Management
- Company typePrivate
- Founded1994
- HeadquartersNew York, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
Deerfield Management firmographics
Firmographics- Name
- Deerfield Management
- Legal name
- Deerfield Management Company, L.P.
- Website
- https://deerfield.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Deerfield Management industry classification
Industry- Product category
- Healthcare Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Investment Advice (6282), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)
Keywords
Where Deerfield Management is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Deerfield Management business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others
Revenue model
- Private Investment Fund Management Fees & Carried Interest: Deerfield Private Design Fund V ($1.4B) and other fund vehicles (Healthcare Innovations Fund III, >$600M) generate revenue through management fees and carried interest on customized private and public investment solutions.
- Investment Advisory Fees: Deerfield is registered under the Investment Advisers Act of 1940 and provides investment advisory services to a limited number of private investment vehicles, charging fees and other compensation disclosed in fund documents.
- Portfolio Company Exits / Capital Gains: Realized returns from sale of portfolio companies (e.g., Melinta Therapeutics sold to CorMedix in September 2025; Nuvalent acquisition by GSK for $10.6B in 2026, generating over $200M for the Deerfield Foundation).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based; not publicly disclosed |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels6 records
Deerfield Management product offering
Product offeringCore offering
Deerfield Management is a healthcare investment management firm that deploys capital and proprietary R&D infrastructure across the healthcare ecosystem. Its core offerings are organized into three pillars: Investment (multiple private funds including the $1.4B Private Design Fund V and $600M+ Healthcare Innovations Fund III, deployed into 40+ portfolio companies and 20+ academic joint ventures), Intelligence (AI/ML and market research applied to drug discovery via the 3DC R&D engine), and Philanthropy (Deerfield Foundation grants and XSeed Awards). The firm provides flexible funding, in-house drug discovery capabilities through 3DC, dedicated workspace at the Cure NYC innovation campus, and long-term strategic co-development partnerships with biopharma, academic medical centers, and healthcare payers.
Product overview
Deerfield Management operates a platform-plus-modules architecture for advancing healthcare through three integrated pillars: Investment, Intelligence, and Philanthropy. At the core is the 3DC (Deerfield Discovery and Development) R&D engine, which is the company's in-house drug discovery platform spanning small molecules and biologics, complemented by Deerfield Catalyst (a medtech incubator) and Cure (a healthcare innovation ecosystem at NYC headquarters housing state-of-the-art labs). The Investment pillar supports portfolio companies and built ventures including Neomorph (molecular glues), Nuvalent (precision oncology), Elion Therapeutics (antifungals), and physician enablement platforms Alo Solutions and Vanova Health; the Intelligence pillar applies AI, data, and market research; and the Philanthropy pillar operates the Deerfield Foundation (including the XSeed Award program) and is supported by strategic collaborations with over 20 academic research institutions.
Differentiator
Problem solved
Functional benefit
Brands
- Deerfield Discovery and Development (3DC): Deerfield's in-house company-building R&D engine that advances early-stage therapeutics from scientific discovery through preclinical proof of concept and into the clinic.
- Genscience
- Deerfield Catalyst
- Cure
- Deerfield Foundation
Products and services
- Deerfield Discovery and Development (3DC) Deerfield's internal research and development engine and company-building R&D platform providing translational biology, drug metabolism and pharmacokinetics, chemistry/CMC, data science, biologics, cell and gene therapy, clinical/regulatory, and project management capabilities for portfolio companies, academic collaborators, and biopharma partners.
- Cure Healthcare Innovation Ecosystem A premier healthcare innovation ecosystem headquartered at 345 Park Avenue South in New York City, housing numerous life science and healthcare companies with in-building laboratory facilities, state-of-the-art equipment, and digital community serving health innovators.
- Deerfield Investment Services (Private Design Fund V and Healthcare Innovations Fund III) Private investment fund management providing flexible funding models to companies across the healthcare ecosystem via multiple fund vehicles including Healthcare Innovations Fund III (over $600M) and Private Design Fund V ($1.4B). Available to private and public companies at all stages of innovation.
- Deerfield Intelligence AI, data, and market research platform driving healthcare technology and innovation forward, integrated across investment, intelligence, and philanthropy functions. Includes Artificial Intelligence and Machine Learning capabilities plus Market Research offerings.
- Deerfield Foundation Not-for-profit philanthropic arm based in New York City that advances innovative healthcare initiatives, awards grants to improve health and accelerate innovation (including $1.5M and $1.4M grant cycles to organizations across seven countries focused on children's health), supports AML research via the ASH Peter Steelman Scholar Award, and operates the XSeed Award program.
- Deerfield Catalyst (Medtech Incubator) Medtech incubator housed at Cure in New York City, committed to developing transformational solutions to improve patient outcomes and streamline care through medical technology incubation.
- Alo Solutions Healthcare services platform built by Deerfield in partnership with Blue Cross Blue Shield of North Carolina that enables independent physicians in North Carolina to manage the business of medicine through physician enablement capabilities.
- Vanova Health Healthcare services platform built by Deerfield with Blue Cross Blue Shield of New Jersey to provide essential tools and services that support independent physician practices; launched as a joint venture.
- Strategic Partnerships Program Bespoke industrial partnership program offering capital, scientific expertise, business and operational support, and access to innovation across the healthcare ecosystem for large biopharma and life-sciences tools companies (J&J Innovation, Lilly, Pfizer, Thermo Fisher, Illumina, Insilico Medicine, Charles River Laboratories, Schrödinger, Relation Therapeutics, BioSymetrics).
- Cure by Deerfield Middle East Health Accelerator 12-week hybrid accelerator program for healthcare startups operating in the Middle East (Doha, Qatar) with mentorship, investor access, and pilot project opportunities, operating alongside the Qatar Investment Authority Fund of Funds VC program and Deerfield's regional office in Doha.
- Genscience Genetics Platform Affiliate genetics platform providing genetic evidence to aid discovery of more effective drug targets; published in Nature on the positive impact of genetic evidence on target discovery.
- Lab of the Future Next-generation AI/ML-enabled laboratory at the Cure NYC healthcare innovation campus funded by a $25 million New York State/Empire State Development grant, leveraging artificial intelligence and machine learning to drastically improve the speed, accuracy, and cost of drug development.
Quantifiable outcome
- $10.6B acquisition of portfolio company Nuvalent by GSK (2026)
- +5 more outcomes
Companies that use Deerfield Management
Customer profileNamed customers12 records
Segments6 records
Ideal customer profiles6 records
Deerfield Management technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature5 records
Deerfield Management partnerships and signals
Strategic signalPartnerships
40 partnerships are on record, tiered past portfolio company (exited), flagship healthcare services partner, flagship clinical partner, strategic partner, flagship biopharma partner, major biopharma partner, partner, flagship academic partner, flagship international academic partner and portfolio company.
- Melinta Therapeuticspast portfolio company (exited)Deerfield acquired Melinta Therapeutics in 2020, growing revenue and product portfolio through leadership and acquisitions, then sold it to CorMedix, Inc. in September 2025. Illustrates Deerfield's integrated financial + operational value creation.
- Blue Cross Blue Shield of North Carolinaflagship healthcare services partnerDeerfield partnered with BCBS North Carolina to build Alo Solutions, a physician enablement platform supporting independent North Carolina physicians managing the business of medicine.
- Horizon Blue Cross Blue Shield of New Jerseyflagship healthcare services partnerJoint venture to support and sustain independent physicians in New Jersey; partnership underlies the Vanova Health platform.
- Hospital for Special Surgery (HSS)flagship clinical partnerAlliance for Innovation in Movement (AIM) launched November 13, 2025 to combine HSS clinical expertise with Deerfield capital, infrastructure, and scientific expertise to develop medical devices, therapeutics, AI-powered digital tools, and consumer technologies for musculoskeletal health and longevity.
- Metis TechBiostrategic partnerMetis TechBio entered a strategic alliance with Deerfield (announced May 28, 2026) to advance AI-driven protein therapeutics and in vivo immunotherapy.
- Johnson & Johnson Innovationflagship biopharma partnerSelect industrial partnership; potential acquisition of projects in areas of partner's interest with access to high-quality and later-stage projects plus industrial-scale resources.
- Eli Lillyflagship biopharma partnerIndustrial partnership; potential access to proprietary novel platforms and ability to "buy in bulk" for multiple projects at one time. Lilly also participates in select Deerfield portfolio deals (e.g., Excelsior Sciences Series A).
- Pfizermajor biopharma partnerIndustrial collaboration partner in Deerfield's select industrial partnerships program.
- Thermo Fisher Scientificmajor biopharma partnerIndustrial collaboration partner in Deerfield's select industrial partnerships program.
- Illuminamajor biopharma partnerIndustrial collaboration partner; also a first-of-its-kind partnership to identify drug targets and accelerate novel therapy development using genomics and artificial intelligence (announced May 5, 2022).
- BioSymetricspartnerIndustrial partnership plus research collaboration (October 31, 2022) using phenomics and genomic data to advance cardiology and neurology targets.
- Relation TherapeuticspartnerIndustrial collaboration partner in Deerfield's select industrial partnerships program.
- Insilico MedicinepartnerIndustrial partnership; access to AI-driven drug discovery and proprietary novel platforms.
- Charles River LaboratoriespartnerIndustrial partnership providing access to expanded marginal workforce and seasoned drug-development experts.
- SchrödingerpartnerIndustrial partnership; access to proprietary computational chemistry platforms.
- Harvard University (Lab1636)flagship academic partnerMajor strategic R&D alliance announced March 2019 to speed the development and translation of biomedical and life-science innovations into transformative treatments.
- NYU Langone Health (Amethyst Innovations)flagship academic partnerR&D collaboration launched June 2023 with up to $130M committed by Deerfield to accelerate commercialization of biomedical discoveries.
- Moffitt Cancer Center (Bayfield Therapeutics)flagship academic partnerTranslational research alliance launched September 2022 with up to $130M committed over 10 years by Deerfield to accelerate cancer therapeutic development.
- Washington University in St. Louis (VeritaScience)flagship academic partnerR&D collaboration launched January 2024 with up to $130M committed by Deerfield over a 10-year commitment to advance therapeutic and diagnostic candidates.
- Dana-Farber Cancer Institute (Riverway Discoveries)flagship academic partnerMajor translational research partnership launched February 2021 with up to $130M committed over 10 years to accelerate cancer therapeutics and diagnostics. Underpins Neomorph and other initiatives.
- University of North Carolina at Chapel Hill (Pinnacle Hill)flagship academic partnerDeerfield-UNC launch announced October 2018 to discover new medicines addressing unmet medical needs. Includes the UNC Eshelman School of Pharmacy "Molecules to Market" Biotherapeutics Certificate Program.
- Yeda / Weizmann Institute of Science (Orchard Innovations)flagship international academic partnerExtensive translational research initiative announced January 2019 — Deerfield's first collaboration outside the USA — to catalyze transformative treatments toward clinical validation.
- Northwestern University (Lakeside Discovery)flagship academic partnerLaunched May 2018 to accelerate translation of transformative biomedical technologies with up to $65M of targeted funding from Deerfield.
- University of Chicago (Hyde Park Discovery)flagship academic partnerCollaboration launched January 2025 with up to $130M committed by Deerfield to accelerate translation of research into life-saving treatments.
- Columbia University (Hudson Heights Innovations)flagship academic partnerMajor R&D alliance announced June 2019 to advance the translation of biomedical discoveries into transformative treatments.
- Cold Spring Harbor Laboratory (Harbor Discoveries)flagship academic partnerR&D collaboration announced January 2023 with up to $130M committed over 10 years by Deerfield to advance next-generation therapeutics.
- University of Michigan (Great Lakes Discovery)flagship academic partnerPartnership announced May 2020 with up to $130M committed by Deerfield to commercialize therapeutic projects.
- Duke University (Four Points Innovation)flagship academic partnerMajor research collaboration announced December 2019 to accelerate the preclinical development of new drugs for improved quality of life and cures for diseases.
- Beth Israel Deaconess Medical Center (Brookline Avenue Innovations)flagship academic partnerResearch collaboration announced September 2022 with up to $130M committed by Deerfield to translate BIDMC research programs from bench to bedside.
- Broad Institute of MIT and Harvardflagship academic partnerPartnership launched October 2017 to tackle serious unmet medical needs; Broad is a highly integrated biomedical and genomic research center with more than 3,000 scientists.
- Baylor College of Medicine (Blue Square Discoveries)flagship academic partnerMajor research collaboration announced May 2021 with up to $130M committed by Deerfield to advance promising therapeutics.
- Johns Hopkins University (Bluefield Innovations)flagship academic partnerCollaboration launched October 2017 to catalyze the development of early-stage therapeutics.
- Boston Children's Hospital (Blackfan Circle Innovations)flagship academic partnerMajor research collaboration announced November 2020 — first Deerfield collaboration with a pediatric research hospital — to advance novel pediatric therapies.
- Vanderbilt University (Ancora Innovation)flagship academic partnerLaunched April 2018 to support Vanderbilt's innovative life science research and leverage Deerfield's drug development expertise.
- Stanford University (Porter Alliance for Innovative Medicines)flagship academic partnerCollaboration announced January 2022 with up to $130M committed by Deerfield to support Stanford's innovative translational research.
- University of Illinois at Chicago (West Loop Innovations)partnerEstablished April 2019 to accelerate the commercialization of therapeutics developed at UIC.
- Empire Discovery Institute (Empire-Deerfield Discovery & Development / ED3)partnerLaunched April 2021 with up to $65M committed by Deerfield over five years to fund translational research.
- Invitaestrategic partnerPartnership announced March 22, 2023 to harness genetic and clinical data from millions of patients tested at Invitae and Deerfield's drug discovery expertise to create novel therapeutics for rare diseases.
- myLaurelportfolio companyDeerfield-affiliated investment ecosystem partner; myLaurel provides technology-enabled, hospital-aligned home care with reported 400% partner increase and 575% surge in patients served in 2025.
- DocereepartnerDeerfield represented among 18 senior agency leaders co-building Daily Command, Doceree's AI-powered operating system for healthcare marketing, which launched May 7, 2026.
Scale indicators8 records
Recent moves8 records
Expansion highlights7 records
Deerfield Management competitors and assessment
Company assessmentDirect peers
- ARCH Venture Partners: ARCH is a long-standing venture capital firm that combines large dedicated life-sciences funds with deep academic medical-center partnerships (e.g., University of Chicago, University of Washington) and in-house science capabilities. Most directly comparable to Deerfield on the integrated capital + academic + in-house R&D model.
- Third Rock Ventures: Third Rock conceives, launches, and operates biotech companies from inception, providing founding teams, R&D infrastructure, and capital — closely mirroring Deerfield's 3DC and Cure-driven company-building motion and its preference for forming companies around academic science.
- Frazier Healthcare Partners: Frazier is a dedicated healthcare investment firm with both growth and life-sciences strategies; comparable to Deerfield on multi-stage healthcare investing and operating company creation (e.g., selling mature portfolio assets to strategic acquirers).
- Versant Ventures: Versant is a healthcare-focused venture firm that both invests in and in-licenses early-stage therapeutics, comparable to Deerfield on the build / co-build approach to biotech creation and on heavy emphasis on therapeutic venture.
- Flagship Pioneering: Flagship builds biotech companies from internal hypotheses and provides both capital and in-house scientific platforms (e.g., the ProFoundry, Generate Biomedicines). Closely comparable to Deerfield on the 'build with the firm' model and on combining generalist VC capital with deep internal R&D infrastructure.
- Polaris Partners: Polaris is a multi-stage venture firm with a strong life-sciences practice that co-founds biotech companies. Comparable to Deerfield on company-building motion and on blending venture capital with operating involvement.
- OrbiMed: OrbiMed is a healthcare-dedicated investment firm across private equity, venture, and public equity. Directly comparable to Deerfield on dedicated healthcare focus, multi-stage fund structure, and broad therapeutic coverage including devices, diagnostics, and therapeutics.
- Venrock: Venrock is a long-tenured venture firm with deep healthcare and biotech expertise (e.g., co-founded several disease-area companies). Comparable to Deerfield on dedicated healthcare practice and on leveraging institutional academic networks for deal flow.
- Atlas Venture: Atlas is a Boston-based early-stage life-sciences VC that builds and seeds biotech companies — comparable to Deerfield on its focus on forming companies around academic science and its therapeutics-only mandate.
Broad incumbents
- New Enterprise Associates (NEA): NEA is a large, multi-stage venture firm with a substantial dedicated healthcare practice. Comparable to Deerfield on scale and multi-stage healthcare deployment, though NEA operates as a broad tech-and-healthcare investor rather than a healthcare-pure-play.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Deerfield Management social profiles
Digital presenceDeerfield Management compliance and trust
Trust signalCompliance3 records
Deerfield Management financial estimates
Financial estimateRevenue estimate
Valuation estimate
Deerfield Management leadership team
Management profileNumber of profiles
Profiles8 records
Deerfield Management subsidiaries and ownership
Company hierarchySubsidiaries35 records
Deerfield Management funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Deerfield Management M&A and investment
M&A and investmentM&A2 records
Investments44 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Deerfield Management
What does Deerfield Management do?
Deerfield Management is a healthcare investment management firm that deploys capital and proprietary R&D infrastructure across the healthcare ecosystem. Its core offerings are organized into three pillars: Investment (multiple private funds including the $1.4B Private Design Fund V and $600M+ Healthcare Innovations Fund III, deployed into 40+ portfolio companies and 20+ academic joint ventures), Intelligence (AI/ML and market research applied to drug discovery via the 3DC R&D engine), and Philanthropy (Deerfield Foundation grants and XSeed Awards). The firm provides flexible funding, in-house drug discovery capabilities through 3DC, dedicated workspace at the Cure NYC innovation campus, and long-term strategic co-development partnerships with biopharma, academic medical centers, and healthcare payers.
Is Deerfield Management a public or private company?
Deerfield Management is a private company. It is classified as management employee owned and is currently operating.
When was Deerfield Management founded?
Deerfield Management was founded in 1994. It employs 101 to 250 people.
Where is Deerfield Management based?
Deerfield Management is headquartered in New York, United States, in the North America region.
How does Deerfield Management make money?
Three revenue lines are on record. Private Investment Fund Management Fees & Carried Interest is the primary driver. The others are investment Advisory Fees and portfolio Company Exits / Capital Gains.
Who are Deerfield Management's main competitors?
Direct peers on record are ARCH Venture Partners, Third Rock Ventures, Frazier Healthcare Partners, Versant Ventures, Flagship Pioneering, Polaris Partners, OrbiMed, Venrock and Atlas Venture. New Enterprise Associates (NEA) is listed as a broad incumbent.
Does Deerfield Management have an API?
No public API is recorded for Deerfield Management.
What industry is Deerfield Management in?
Deerfield Management's product category is Healthcare Investment Management. Its primary akta.pro industry code is FSANAAAJ, Venture Capital Fund-of-Funds / Multi-Manager Platforms. Its NAICS code is 523940 and its SIC code is 6282.